RE:RE:FDA’s Decision to Approve New Treatment for Alzheimer’s DiseYes!! Word needs to get out that ARFXF PHI funding tied to aducanumab approval, and that PMN310 is a better version of aducanumab that can be dosed at higher levels without expected side effects.
And for investors, that PMN's market cap is about 1000X smaller than BIIB, so the real money to be made is in PMN! BIIB calls might be doing pretty well too- congrats TB. I stayed away from those because they were not cheap on the entry side. Hope that works out for you though.
ARFXF/PMN.TO is like the average person's BIIB call option this week. HERE WE GO!!!